It's yet another patent-infringement lawsuit for TevaPharmaceuticals
In a U.S. District Court filing, Eisai charged that Teva's plans to begin developing a generic version of its popular drug Aricept infringe on the patent of the treatment's active ingredient, donepezil hydrochloride, which has protection until 2010. Eisai further said it will "vigorously enforce and defend" that patent. Though Teva did not respond to the accusation, the company is often subject to patent infringement lawsuits, which stem from its aggressive encroachment on drugs that near patent expiration.
It's not surprising, really, that Teva would seek to develop a generic version of Aricept. Co-marketed with pharmaceutical giant Pfizer
Generic drugs are set to enjoy a banner year in 2006. Six blockbuster drugs with sales of more than $1 billion each are set to go off-patent in the U.S., ranging from Merck's
Maintaining their patent advantage over generic drug companies will require the pharmaceutical giants to improve upon the drug profiles in their portfolios. While Teva or MylanLabs
With an estimated 10% share of the generic drug market, Teva is poised to continue leading the pack. Of course, that's assuming it can remember to respect patents and avoid costly litigation that might erode shareholder value.
We've recalled further Foolishness:
Fools, now is the time to open your hearts and wallets to worthy causes! Please support our five Foolish charities at www.foolanthropy.com.